Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Amoxicillin/clavulanate emerges as best antibiotic for childhood bronchiectasis

Key clinical point: Relative to azithromycin for nonsevere bronchiectasis in children, amoxicillin/clavulanate was more effective.

Major finding: Relative to placebo, the risk ratio for exacerbation resolution was higher for amoxicillin/clavulanate (risk ratio, 1.5) than azithromycin (RR, 1.4)

Data Source: Double-blind, multicenter, placebo-controlled trial.

Disclosures: Dr. Goyal reported no potential conflicts of interest.

Citation:

Goyal V et al. Lancet Respir Med. 2019;7:791-801.